URGN Q4 2023 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$927M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$24M+30.1% YoY

Gross Profit

$21M90.3% margin

Operating Income

-$15M-62.1% margin

Net Income

-$26M-110.6% margin

EPS (Diluted)

$-0.72

QoQ Revenue Growth

+12.8%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$178M

Total Liabilities

$244M

Stockholders' Equity

-$65M

Cash & Equivalents

$96M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$24M	$18M	+30.1%
Gross Profit	$21M	$16M	+34.2%
Operating Income	-$15M	-$20M	+28.0%
Net Income	-$26M	-$29M	+9.9%

Revenue Segments

Jelmyto

$44M100%